BRAF and cancer: In a retrospective study including seven participating Israeli cancer centers reported by Dudnik et al., PD-L1 expression level, tumor mutational burden (TMB), and microsatellite instability status were assessed in both BRAF V600E and non-V600E BRAF mutation positive NSCLC, and the outcome with ICI treatment was reported (43).